Committees for ethics in research involving human subjects
Journal International de Bioethique, v. 19, n. 1-2, p. 131-141, 2008.
Saad Hossne, William
Bontempo Duca de Freitas, Corina
In Brazil since October 1996 there have been guidelines for research involving human subjects. Now human subjects know when their treatment is part of research. Deceit is no longer tolerated. But is not enough to say we offer an explanation to the potential subject and we offer a choice before he or she is confronted with an informed consent form. As in all professional activity, scientific investigation needs social controls. In Brazil, the ultimate responsibility of an investigation lies on the investigator, but in every institution where research is carried out there is a Committee for Ethics in Research. All Committees are subordinated to the National Commission of Ethics in Research, which is submitted to the Brazilian Institute of Health. During 2005 around 17,000 protocols involving 700,000 human subjects were revised by 475 Committees distributed all over the country. Approximately 7,000 people are now working in these Committees.
Showing items related by title, author, creator and subject.
Universidade Estadual Paulista (UNESP); University of São Camilo; Universidade Estadual de Campinas (UNICAMP); Graduate School of Health Sciences (2008-03-01)In Brazil since October 1996 there have been guidelines for research involving human subjects. Now human subjects know when their treatment is part of research. Deceit is no longer tolerated. But is not enough to say we ...
A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): Study protocol for a randomized double-blind controlled trial Fuchs, Flávio D.; Fuchs, Sandra C.; Moreira, Leila B.; Gus, Miguel; Nóbrega, Antônio C.; Poli-de-Figueiredo, Carlos E.; Mion, Décio; Bortolotto, Luiz; Consolim-Colombo, Fernanda; Nobre, Fernando; Coelho, Eduardo B.; Vilela-Martin, José F.; Moreno Jr, Heitor; Cesarino, Evandro J.; Franco, Roberto; Brandão, Andréa A.; de Sousa, Marcos R.; Pinho Ribeiro, Antônio L.; Jardim, Paulo C.; Neto, Abrahão A.; Scala, Luiz C.N.; Mota, Marco; Chaves, Hilton; Alves, João G.; Sobral Filho, Dario C.; e Silva, Ricardo P.; Figueiredo Neto, José A.; Irigoyen, Maria C.; Castro, Iran; Steffens, André A.; Schlatter, Rosane; de Mello, Renato B.; Mosele, Francisca; Ghizzoni, Flávia; Berwanger, Otávio
A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): Study protocol for a randomized double-blind controlled trial Universidade Federal do Rio Grande do Sul (UFRGS); Universidade Federal Fluminense (UFF); Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS); Universidade de São Paulo (USP); São José do Rio Preto; Universidade Estadual de Campinas (UNICAMP); Universidade Estadual Paulista (UNESP); Universidade do Estado do Rio de Janeiro (UERJ); Universidade Federal de Minas Gerais (UFMG); Universidade Federal de Goiás (UFG); Anis Rassi Hospital; Universidade Federal de Mato Grosso; Universidade de Ciências da Saúde Alagoas; Universidade Federal de Pernambuco (UFPE); Instituto de Medicina Integral Prof Fernando Figueira; Universidade de Pernambuco; Universidade Federal do Ceará (UFC); Universidade Federal Maranhão; Fundação Universitária de Cardiologia; Universidade Federal de Pelotas (UFPEL); Hospital do Coração (2011-02-24)Background: Cardiovascular disease is the leading cause of death in Brazil, and hypertension is its major risk factor. The benefit of its drug treatment to prevent major cardiovascular events was consistently demonstrated. ...